A
ARTIVA BIOTHERAPEUTICS, INC. COMMON STOCK
NASDAQ: ARTV (Artiva Biotherapeutics, Inc.)
最近更新时间: 17分钟之前4.18
-0.02 (-0.36%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Artiva Biotherapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.7 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | 0.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.84 |
|
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 19.99% |
| 机构持股比例 | 89.73% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ra Capital Management, L.P. | 30 Jun 2026 | 17,955,642 |
| Viking Global Investors Lp | 30 Jun 2026 | 2,604,166 |
| Blackstone Inc. | 30 Jun 2026 | 2,403,437 |
| 5Am Venture Management, Llc | 30 Jun 2026 | 2,353,304 |
| Venrock Adviser, Llc | 30 Jun 2026 | 2,043,596 |
| Caligan Partners Lp | 30 Jun 2026 | 1,736,111 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 954,861 |
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 874,542 |
| Propel Bio Management, Llc | 30 Jun 2026 | 696,436 |
| Silverarc Capital Management, Llc | 30 Jun 2026 | 525,000 |
该时间范围内无数据。
投资组合